NeuroPace (NPCE) Stock Price, News & Analysis

Company Overview

NeuroPace, Inc. is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals. The system continuously monitors brain activity and records relevant neurological data, which can help physicians personalize treatment and evaluate patient response over time.

NeuroPace was founded in 1997 and received U.S. Food and Drug Administration approval for the RNS System in 2013. The company is headquartered in Mountain View, California, and primarily serves patients and healthcare providers in the United States through specialized epilepsy centers. Its activities also include clinical research and the development of software and related technologies intended to support epilepsy care.

Key Stats

• Today's Range: $12.25 to $13.10
• 50-Day Range: $12.24 to $15.19
• 52-Week Range: $9.22 to $19.60
• Volume: 80,901 shs
• Average Volume: 102,654 shs
• Market Capitalization: $422.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.33
• Consensus Rating: Moderate Buy

NeuroPace Stock Analysis - MarketRank™

NeuroPace scored higher than 68% of companies evaluated by MarketBeat, and ranked 271st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NeuroPace has a consensus price target of $19.33, representing about 57.2% upside from its current price of $12.30.

Amount of Analyst Coverage

NeuroPace has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroPace are expected to grow in the coming year, from ($0.67) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroPace is -21.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroPace is -21.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroPace has a P/B Ratio of 21.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.20% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 8.27.

Change versus previous month

Short interest in NeuroPace has recently decreased by 1.93%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroPace does not currently pay a dividend.

Dividend Growth

NeuroPace does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

NeuroPace has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NeuroPace this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroPace insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NPCE
• CIK: 1528287
• Web: www.neuropace.com
• Phone: 650-237-2700
• Fax: N/A
• Employees: 220
• Year Founded: 1997

Price Target and Rating

• Average Price Target for NeuroPace: $19.33
• High Price Target: $22.00
• Low Price Target: $16.00
• Potential Upside/Downside: +57.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: -19.34%
• Pretax Margin: -17.96%
• Return on Equity: -105.64%
• Return on Assets: -16.51%

Debt

• Debt-to-Equity Ratio: 4.97
• Current Ratio: 4.94
• Quick Ratio: 3.91

Sales & Book Value

• Annual Sales: $99.99 million
• Price / Sales: 4.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 21.58

Miscellaneous

• Outstanding Shares: 34,320,000
• Free Float: 27,734,000
• Market Cap: $422.14 million
• Optionable: Optionable
• Beta: 1.86